# A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

> **NCT05557565** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** QL1706

## Key facts

- **NCT ID:** NCT05557565
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-21
- **Primary completion:** 2022-10-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05557565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05557565, "A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05557565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*